Collegium Pharmaceutical (NASDAQ:COLL) Hits New 52-Week Low – Time to Sell?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) reached a new 52-week low during trading on Wednesday . The stock traded as low as $28.38 and last traded at $28.47, with a volume of 214570 shares changing hands. The stock had previously closed at $28.82.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the company. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research note on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, Piper Sandler lowered their price objective on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Collegium Pharmaceutical presently has an average rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Price Performance

The stock has a market cap of $914.29 million, a price-to-earnings ratio of 12.22 and a beta of 0.82. The company has a 50-day simple moving average of $30.91 and a two-hundred day simple moving average of $33.58. The company has a debt-to-equity ratio of 3.43, a quick ratio of 0.88 and a current ratio of 0.97.

Insider Buying and Selling

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 27,500 shares of Collegium Pharmaceutical stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the transaction, the executive vice president now owns 119,184 shares of the company’s stock, valued at $3,937,839.36. This trade represents a 18.75 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 3.98% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

Institutional investors and hedge funds have recently made changes to their positions in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Collegium Pharmaceutical by 11.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 66,389 shares of the specialty pharmaceutical company’s stock valued at $1,902,000 after buying an additional 7,063 shares during the last quarter. Velan Capital Investment Management LP bought a new stake in shares of Collegium Pharmaceutical during the 4th quarter valued at $822,000. Vident Advisory LLC raised its stake in Collegium Pharmaceutical by 27.8% during the 4th quarter. Vident Advisory LLC now owns 16,898 shares of the specialty pharmaceutical company’s stock valued at $484,000 after purchasing an additional 3,672 shares during the period. Virtus Fund Advisers LLC boosted its stake in Collegium Pharmaceutical by 30.5% during the fourth quarter. Virtus Fund Advisers LLC now owns 2,419 shares of the specialty pharmaceutical company’s stock valued at $69,000 after buying an additional 565 shares during the last quarter. Finally, State of Wyoming lifted its position in Collegium Pharmaceutical by 75.0% during the fourth quarter. State of Wyoming now owns 9,818 shares of the specialty pharmaceutical company’s stock valued at $281,000 after purchasing an additional 4,208 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.